Home

Roy C. Hardiman

CIK 1506218 · Chief Business & Strategy Ofcr · last filed 2026-01-28

Roy C. Hardiman is a Chief Business & Strategy Ofcr who has filed 20 SEC Form 4 insider transactions across 2 companies since 2019. The most recent filing, for ALMS, was dated Jan 28, 2026. Across all open-market trades the lifetime net is −$1.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.7M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$5.74M

Companies

2

Total Filings

20

Lifetime Open-Market Net

-$1.30M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ALMS Chief Business & Strategy Ofcr 212,818 $26.96 $5.74M $0 4 2026-01-28
Principia Biopharma Inc. (PRNB) Delisted Chief Business Officer 0 — — -$1.30M 7 2020-09-28

Recent Filings

20 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-01-28 ALMS Grant (A) — $0 EDGAR
2025-07-31 ALMS Grant (A) +28,000 $0 EDGAR
2025-02-20 ALMS Grant (A) — $0 EDGAR
2024-07-01 ALMS Mixed — $0 EDGAR
2020-09-28 Principia Biopharma Inc. (PRNB) Delisted Mixed −119,677 -$11.97M EDGAR
2020-09-22 Principia Biopharma Inc. (PRNB) Delisted Mixed — -$470.6K EDGAR
2020-06-15 Principia Biopharma Inc. (PRNB) Delisted Mixed — -$282.2K EDGAR
2020-03-17 Principia Biopharma Inc. (PRNB) Delisted Mixed — -$219.2K EDGAR
2020-03-05 Principia Biopharma Inc. (PRNB) Delisted Grant (A) — $0 EDGAR
2019-12-13 Principia Biopharma Inc. (PRNB) Delisted Mixed — -$222.3K EDGAR
Showing 1–10 of 20
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.